A Phase 2 interventional study of Pitolisant Oral Tablet and Placebo oral tablet in Myotonic Dystrophy 1 and Excessive Daytime Sleepiness, sponsored by Harmony Biosciences Management, Inc.. Completed at 13 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-04.
Sponsored by Harmony Biosciences Management, Inc. (part of Harmony Biosciences Holdings, Inc.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Myotonic Dystrophy with a site in United States — 23 open to participants now, 27 under way, 4 of them phase 3. Myotonic Dystrophy · United States.
Among the 43 studies in Myotonic Dystrophy with a site in United States, this one is the 18th largest by enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2021, is one of 5 in phase 2, and was the 16th registered.
126 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.
Browse Myotonic Dystrophy studies →23 of the 43 studies in Myotonic Dystrophy with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 14+ · Healthy volunteers
Virginia Commonwealth University · Sites in United States
Ages 18–70
Dyne Therapeutics · Sites in United States
Ages 4–18 · Men only
Dyne Therapeutics · Sites in United States, Australia, Belgium and 9 more countries
Ages 16+
Sanofi · Sites in United States, Argentina, Australia and 3 more countries
Ages 10–55
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 35 Myotonic Dystrophy studies recruiting now, 15 (43%) set no upper age limit and 18 (51%) stop at 75 or younger; 22 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 14 · Phase 3 6
First in 2000; this study’s year is marked. 4 started in 2021.
This study's enrollment of 30 is below the median of 40 across 67 interventional studies indexed under Myotonic Dystrophy.
Median enrollment 46 across the 22 interventional studies, 125 across the 21 observational. Of the 15 that completed or were terminated, 7 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 43 have an industry lead sponsor. The 10 most frequent:
This study is registered under Harmony Biosciences Management, Inc., one of the names counted as Harmony Biosciences Holdings, Inc.. Under that name alone:
Harmony Biosciences Management, Inc. is the lead sponsor of 16 studies on the registry; 6 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 5 (63%) have results posted.
Harmony Biosciences Holdings, Inc. has 1 study filed under Myotonic Dystrophy — fewer than ten, so there is no comparison to draw.
9 of the studies in Myotonic Dystrophy with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05004129Phase 3AMO Pharma LimitedSafety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy | 2026-12-31 |
| NCT05020002Massachusetts General HospitalExtracellular RNA Biomarkers of Myotonic Dystrophy | 2026-12 |
| NCT05224778Virginia Commonwealth UniversityDMCRN-02-001: Assessing Pediatric Endpoints in DM1 | 2026-12 |
| NCT03981575Virginia Commonwealth UniversityEstab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) | 2026-12-01 |
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
Add all 9 to your calendar (.ics) → With an account.
Among the 43 studies in Myotonic Dystrophy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the safety and efficacy of pitolisant compared with placebo in treating excessive daytime sleepiness (EDS) in patients with Myotonic Dystrophy Type 1 ages 18 to 65 years.
The secondary objectives of this study are to assess the impact of pitolisant on fatigue, cognitive function and the burden of disease along with assessing the long-term safety and effectiveness of pitolisant in patients with Myotonic Dystrophy Type 1 ages 18 to 65 years.
The study will consist of a Screening Period, an 11-week Double-Blind Treatment Phase (including a 3-week Titration Period and an 8-week Stable Dose Period), and an optional Open Label Extension (OLE) Phase. The OLE Phase will last approximately one year for each patient or until the Sponsor elects to terminate the study.
Approximately 30 patients ages 18 to 65 years who meet all eligibility criteria will be randomized at the Baseline Visit in a 1:1:1 ratio to lower dose pitolisant, higher dose pitolisant, or matching placebo. In the Double-Blind Treatment Phase, patients will be titrated to their randomized stable dose of study drug during the 3-week Titration Period.
After completion of the 3-week Titration Period, patients will continue to take study drug at their randomized stable dose once daily in the morning upon wakening for an additional 8 weeks of blinded treatment (Stable Dose Period). The duration of the Double-Blind Treatment Phase will be 11 weeks.
Following the 11-week Double-Blind Treatment Phase, eligible patients will be given the opportunity to participate in an optional OLE Phase. During the OLE Phase, all eligible patients will receive treatment with open-label pitolisant. Patients will first undergo a 3-week Titration Period to a maximum target dose, after which they will continue to take their dose of pitolisant once daily in the morning upon wakening until the end of the study. The patient's dose of pitolisant may be adjusted during the OLE phase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
If on a wake-promoting treatment that could affect EDS (including stimulants, modafinil, and armodafinil):
Exclusion Criteria:
Electrocardiogram abnormalities during a 10-second, 12-lead ECG at Screening of first degree atrioventricular block (AVB; PR interval >220 msec), QRS >120 msec, heart rate (HR) \<50 beats per minute (bpm), marked T-wave abnormalities, more than single atrial premature complexes (APCs) or premature ventricular contractions (PVCs), left bundle branch block, or Brugada pattern type 1.
Note: Patients with 1st degree AVB with a PR interval >220 msec, who are treated prophylactically with an allowable implanted device are not excluded from the study.
Is receiving a concomitant medication that is known to be a strong cytochrome P450 (CYP) 2D6 inhibitor, a strong inducer; or a centrally acting histamine 1 receptor (H1R) antagonist (sedating antihistamine).
Note: Patients who undergo a washout of these medications of at least 5 half-lives may be enrolled in the Double-Blind Treatment Phase of the study.
Note: Use of strong CYP2D6 inhibitors and strong CYP3A4 inducers is allowed during the OLE Phase; however, adjustment of pitolisant dose is required. Although not prohibited during the OLE Phase of the study, use of centrally acting or sedating H1R antagonists should be avoided.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Double-Blind Treatment Phase: Week 1: 8.9 mg pitolisant administered once daily in the morning; Week 2: 17.8 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 35.6 mg pitolisant administered once daily in the morning.
Drug: Pitolisant Oral Tablet
Double-Blind Treatment Phase: Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 17.8 mg pitolisant administered once daily in the morning
Drug: Pitolisant Oral Tablet
Double-Blind Treatment Phase: Week 1: Matching placebo tablets; Week 2: Matching placebo tablets; Weeks 3 through 11: Matching placebo tablets
Drug: Placebo oral tablet
Pitolisant 4.45 mg tablets: white, round, plain, biconvex film-coated tablet, 3.7 mm in diameter. Each tablet contains 5 mg of pitolisant hydrochloride equivalent to 4.45 mg of pitolisant. Pitolisant 17.8 mg tablets: white, round, plain, biconvex film-coated tablet, 7.5 mm in diameter. Each tablet contains 20 mg of pitolisant hydrochloride equivalent to 17.8 mg of pitolisant.
Matching placebo tablets will be provided for each strength of active pitolisant film-coated tablets.
Change in Excessive Daytime Sleepiness (EDS) Based on Change in Daytime Sleepiness Scale (DSS) Score
The score of the DSS ranges from 0 to 15. A decrease in the DSS score represents an improvement in EDS.
Time frame: Baseline to Week 11
Change in Fatigue Based on Change in Fatigue Severity Scale (FSS) Score
The score of the FSS ranges from 0 to 63. A decrease in the FSS score represents an improvement in fatigue.
Time frame: Baseline to Week 11
Change in Psychomotor Function Based on Change in Cogstate Detection Test
The Cogstate Detection Test is a computerized test. A faster speed represents an improvement in psychomotor test performance.
Time frame: Baseline to Week 11
Change in Attention Based on Change in Cogstate Identification Test
The Cogstate Identification Test is a computerized test. A faster speed represents an improvement in attention test performance.
Time frame: Baseline to Week 11
Change in Working Memory Based on Change in Cogstate One Back Test
The Cogstate One Back Test is a computerized test. A faster speed represents a better working memory test performance.
Time frame: Baseline to Week 11
Change in Burden of Disease Based on Change in Myotonic Dystrophy Health Index (MDHI)
The MDHI score ranges from 0 to 100. A decrease in the MDHI score represents an improvement in overall burden of disease.
Time frame: Baseline to Week 11
Change in Excessive Daytime Sleepiness (EDS) Based on Change in Epworth Sleepiness Scale (ESS) Score
The score of the ESS ranges from 0 to 24. A decrease in the ESS score represents an improvement in EDS.
Time frame: Baseline to Week 11
Change in Excessive Daytime Sleepiness (EDS) Based on Change in Clinical Global Impression of Severity (CGI-S)
The CGI-S is a one-item scale that ranges from 0 to 4 with 0 being no EDS and 4 being severe EDS. The scale is completed by the site investigator/clinician. The higher the CGI-S score, the more severe the clinician's perception of the patient's symptoms of EDS.
Time frame: Baseline to Week 11
Change in Excessive Daytime Sleepiness (EDS) Based on Change in Patient Global Impression of Severity (PGI-S)
PGI-S is a one-item scale that ranges from 0 to 4 with 0 being no EDS and 4 being severe EDS. The scale is completed by the patient. The higher the PGI-S score, the more severe the patient's perception of excessive daytime sleepiness.
Time frame: Baseline to Week 11
Change in Sustained Attention Based on Sustained Attention to Response Task (SART)
The Sustained Attention to Response Test provides a measure of vigilance and sustained attention. A number ranging from 1 to 9 is presented on screen. The subject must press a predetermined button (the YES external button) as soon as the number is presented, except when the number is a 3. The number 3 is the default number (no-go stimulus) for which a response should be inhibited, and the subject should not press the predetermined button. The no-go stimulus can be configured to be a number other than 3. Performance is measured by calculating the number of errors made during the test over the course of 225 trials. Performance is measured by calculating the error score, which is the sum of trials where a response was provided when a 3 was presented and trials where no response was provided when a number other than 3 was presented. A decrease in the SART score represents an improvement in sustained attention.
Time frame: Baseline to Week 11
| Milestone | Higher Dose Pitolisant (DBTP) | Lower Dose Pitolisant (DBTP) | Placebo (DBTP) | Pitolisant (OLE) |
|---|---|---|---|---|
| Started | 10 | 10 | 10 | 0 |
| Completed | 8 | 9 | 10 | 0 |
| Not completed | 2 | 1 | 0 | 0 |
| Withdrew: Other: not specified | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 |
| Milestone | Higher Dose Pitolisant (DBTP) | Lower Dose Pitolisant (DBTP) | Placebo (DBTP) | Pitolisant (OLE) |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 24 |
| Completed | 0 | 0 | 0 | 15 |
| Not completed | 0 | 0 | 0 | 9 |
| Withdrew: Adverse event | 0 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 6 |
| Withdrew: Other: not specified | 0 | 0 | 0 | 1 |
The score of the DSS ranges from 0 to 15. A decrease in the DSS score represents an improvement in EDS.
| score on a scale | Higher Dose Pitolisant | Lower Dose Pitolisant | Placebo |
|---|---|---|---|
| Change in Excessive Daytime Sleepiness (EDS) Based on Change in Daytime Sleepiness Scale (DSS) Score | -3.8 ± 1.98 | -1.8 ± 1.91 | 0.0 ± 2.29 |
The score of the FSS ranges from 0 to 63. A decrease in the FSS score represents an improvement in fatigue.
| score on a scale | Higher Dose Pitolisant | Lower Dose Pitolisant | Placebo |
|---|---|---|---|
| Change in Fatigue Based on Change in Fatigue Severity Scale (FSS) Score | -0.86 ± 1.487 | -0.36 ± 0.367 | -0.13 ± 0.529 |
The Cogstate Detection Test is a computerized test. A faster speed represents an improvement in psychomotor test performance.
| log10 ms | Higher Dose Pitolisant | Lower Dose Pitolisant | Placebo |
|---|---|---|---|
| Change in Psychomotor Function Based on Change in Cogstate Detection Test | 0.02 ± 0.058 | -0.05 ± 0.061 | 0.01 ± 0.037 |
The Cogstate Identification Test is a computerized test. A faster speed represents an improvement in attention test performance.
| log10 ms | Higher Dose Pitolisant | Lower Dose Pitolisant | Placebo |
|---|---|---|---|
| Change in Attention Based on Change in Cogstate Identification Test | 0.00 ± 0.035 | -0.02 ± 0.076 | -0.02 ± 0.052 |
The Cogstate One Back Test is a computerized test. A faster speed represents a better working memory test performance.
| log10 ms | Higher Dose Pitolisant | Lower Dose Pitolisant | Placebo |
|---|---|---|---|
| Change in Working Memory Based on Change in Cogstate One Back Test | 0.00 ± 0.062 | -0.01 ± 0.032 | 0.00 ± 0.050 |
The MDHI score ranges from 0 to 100. A decrease in the MDHI score represents an improvement in overall burden of disease.
| score on a scale | Higher Dose Pitolisant | Lower Dose Pitolisant | Placebo |
|---|---|---|---|
| Change in Burden of Disease Based on Change in Myotonic Dystrophy Health Index (MDHI) | -9.14 ± 13.277 | -2.89 ± 8.510 | 0.42 ± 5.529 |
The score of the ESS ranges from 0 to 24. A decrease in the ESS score represents an improvement in EDS.
| score on a scale | Higher Dose Pitolisant | Lower Dose Pitolisant | Placebo |
|---|---|---|---|
| Change in Excessive Daytime Sleepiness (EDS) Based on Change in Epworth Sleepiness Scale (ESS) Score | -4.9 ± 3.98 | 1.3 ± 2.83 | -0.1 ± 2.51 |
The CGI-S is a one-item scale that ranges from 0 to 4 with 0 being no EDS and 4 being severe EDS. The scale is completed by the site investigator/clinician. The higher the CGI-S score, the more severe the clinician's perception of the patient's symptoms of EDS.
| score on a scale | Higher Dose Pitolisant | Lower Dose Pitolisant | Placebo |
|---|---|---|---|
| Change in Excessive Daytime Sleepiness (EDS) Based on Change in Clinical Global Impression of Severity (CGI-S) | -0.9 ± 0.64 | -0.2 ± 0.44 | -0.1 ± 0.32 |
PGI-S is a one-item scale that ranges from 0 to 4 with 0 being no EDS and 4 being severe EDS. The scale is completed by the patient. The higher the PGI-S score, the more severe the patient's perception of excessive daytime sleepiness.
| score on a scale | Higher Dose Pitolisant | Lower Dose Pitolisant | Placebo |
|---|---|---|---|
| Change in Excessive Daytime Sleepiness (EDS) Based on Change in Patient Global Impression of Severity (PGI-S) | -0.5 ± 0.76 | 0.0 ± 1.0 | -0.4 ± 0.84 |
The Sustained Attention to Response Test provides a measure of vigilance and sustained attention. A number ranging from 1 to 9 is presented on screen. The subject must press a predetermined button (the YES external button) as soon as the number is presented, except when the number is a 3. The number 3 is the default number (no-go stimulus) for which a response should be inhibited, and the subject should not press the predetermined button. The no-go stimulus can be configured to be a number other than 3. Performance is measured by calculating the number of errors made during the test over the course of 225 trials. Performance is measured by calculating the error score, which is the sum of trials where a response was provided when a 3 was presented and trials where no response was provided when a number other than 3 was presented. A decrease in the SART score represents an improvement in sustained attention.
| scores on a scale | Higher Dose Pitolisant | Lower Dose Pitolisant | Placebo |
|---|---|---|---|
| Change in Sustained Attention Based on Sustained Attention to Response Task (SART) | -2.33 ± 5.428 | 1.43 ± 4.467 | 21.88 ± 68.689 |
Collected over DBTP: First dose of study drug in DBTP up to 11 weeks; OLE Phase: First dose of study drug in OLE phase up to 62 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Higher Dose Pitolisant (DBTP) | 0/10 (0%) | 0/10 (0%) | 8/10 (80%) |
| Lower Dose Pitolisant (DBTP) | 0/10 (0%) | 0/10 (0%) | 7/10 (70%) |
| Placebo (DBTP) | 0/10 (0%) | 0/10 (0%) | 8/10 (80%) |
| Pitolisant (OLE) | 0/24 (0%) | 2/24 (8.3%) | 16/24 (66.7%) |
| Event | Higher Dose Pitolisant (DBTP) | Lower Dose Pitolisant (DBTP) | Placebo (DBTP) | Pitolisant (OLE) |
|---|---|---|---|---|
| Foot fractureInjury, poisoning and procedural complications | 0/10 | 0/10 | 0/10 | 1/24 |
| Precursor T-lymphoblastic lymphoma/leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/10 | 0/10 | 0/10 | 1/24 |
| Event | Higher Dose Pitolisant (DBTP) | Lower Dose Pitolisant (DBTP) | Placebo (DBTP) | Pitolisant (OLE) |
|---|---|---|---|---|
| HeadacheNervous system disorders | 5/10 | 1/10 | 3/10 | 3/24 |
| InsomniaPsychiatric disorders | 1/10 | 4/10 | 3/10 | 6/24 |
| NauseaGastrointestinal disorders | 3/10 | 1/10 | 1/10 | 1/24 |
| COVID-19Infections and infestations | 0/10 | 2/10 | 2/10 | 3/24 |
| Decreased appetiteMetabolism and nutrition disorders | 2/10 | 1/10 | 0/10 | 1/24 |
| MigraineNervous system disorders | 2/10 | 0/10 | 0/10 | 1/24 |
| AnxietyPsychiatric disorders | 0/10 | 2/10 | 0/10 | 2/24 |
| ConstipationGastrointestinal disorders | 0/10 | 0/10 | 0/10 | 3/24 |
| Gastroenteritis viralInfections and infestations | 0/10 | 0/10 | 0/10 | 3/24 |
| NasopharyngitisInfections and infestations | 0/10 | 0/10 | 0/10 | 3/24 |
Baseline characteristics are provided for the double-blind safety population which included all participants who are enrolled and took at least one dose of double-blind study drug.
| Age, Categorical(Participants) | Higher Dose Pitolisant | Lower Dose Pitolisant | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 10 | 10 | 10 | 30 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Higher Dose Pitolisant | Lower Dose Pitolisant | Placebo | Total |
|---|---|---|---|---|
| Median | 36.5 (20 to 55) | 42.0 (28 to 50) | 41.0 (27 to 60) | 40.0 (20 to 60) |
| Sex: Female, Male(Participants) | Higher Dose Pitolisant | Lower Dose Pitolisant | Placebo | Total |
|---|---|---|---|---|
| Female | 4 | 4 | 5 | 13 |
| Male | 6 | 6 | 5 | 17 |
| Ethnicity (NIH/OMB)(Participants) | Higher Dose Pitolisant | Lower Dose Pitolisant | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 1 |
| Not Hispanic or Latino | 9 | 10 | 10 | 29 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Higher Dose Pitolisant | Lower Dose Pitolisant | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 9 | 10 | 10 | 29 |
| More than one race | 1 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Higher Dose Pitolisant | Lower Dose Pitolisant | Placebo | Total |
|---|---|---|---|---|
| Canada | 4 | 5 | 3 | 12 |
| United States | 6 | 5 | 7 | 18 |
| Daytime Sleepiness Scale (DSS)(units on a scale) | Higher Dose Pitolisant | Lower Dose Pitolisant | Placebo | Total |
|---|---|---|---|---|
| Mean | 8.5 ± 3.21 | 7.3 ± 1.16 | 7.9 ± 3.22 | 7.8 ± 2.74 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2021 to primary completion in Oct 2023, 27 months.
Results were first posted in Apr 2025, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pitolisant
Harmony Biosciences Management, Inc. →